SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...

Elsewhere, new pharma launches grew 67.1% to 727 million euros ($787), with hemophilia med Altuviiio, Pompe disease treatment Nexviazyme and Rezurock for graft-versus-host disease leading the charge.

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia drug ...

They were driven by new pharmaceutical launches (up 67.1% to €727 million), including Altuviiio, used to treat haemophilia, Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, ...

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus. Investors ...

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus. Investors ...